NCT05131438View on ClinicalTrials.gov

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

Not specified

Conditions
Extranodal NK/T-cell Lymphoma
Interventions
DRUG

sugemalimab

sugemalimab (Anti-PD-L1 antibody)

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

EQRx International, Inc.

INDUSTRY